Login to Your Account

Amgen Among First Impacted By New Reimbursement Plan

By Kim Coghill

Monday, November 4, 2002
It appears that Amgen Inc. could fall victim to a government reimbursement program that calls its anemia drug Aranesp "functionally equivalent" to a similar product, Procrit, made by Johnson & Johnson. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription